-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on BridgeBio Pharma, Lowers Price Target to $91

Benzinga·10/19/2026 20:49:05
Listen to the news
Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and lowers the price target from $94 to $91.